CONFIDENTIAL — APPROVED FOR PUBLIC RELEASE · BUREAU FILE COPY RECORDS CURRENT AS OF 29 MAY 2026 · DISTRIBUTION: UNRESTRICTED
VendorInvestigator Independent Testing Bureau · Public Records Division
DOCKET YEAR 2026 · VOL. II
35,156 SAMPLES ON FILE
No fee · No favor
Compound Evidence File
#EC-2026-0837

Methylamine (base) CAS 74-89-5

Filed under Raw Materials. The bureau holds 115 laboratory returns for this compound from 35 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.

Cross-Index

Subjects Shipping This Compound

35 SUBJECTS
SubjectGradeSamplesMeanMinMaxFirst seenLast seen
Tianjin Finder Chemical TFCCASE #VI-2026-0693 A 6 10.0 9.9 10.0 14 Nov 2025 16 Apr 2026
Sigma-AldrichCASE #VI-2026-0829 A 4 10.0 10.0 10.0 9 Apr 2026 15 Aug 2026
Thermo Fisher ScientificCASE #VI-2026-0142 A 4 10.0 10.0 10.0 1 Jan 2026 9 Jul 2026
Hubei JianxiangCASE #VI-2026-0048 A 3 10.0 9.9 10.0 8 Jan 2026 26 May 2026
Shanghai Sigma AudleyCASE #VI-2026-0505 A 3 10.0 9.9 10.0 12 Dec 2025 23 Jul 2026
Hybio PharmaceuticalCASE #VI-2026-0065 A 3 10.0 9.9 10.0 5 Dec 2025 23 May 2026
PolyPeptide GroupCASE #VI-2026-0143 A 3 10.0 9.9 10.0 16 Feb 2026 21 Jul 2026
SinoPepCASE #VI-2026-0387 A 3 10.0 10.0 10.0 8 Apr 2026 26 Jul 2026
AsymchemCASE #VI-2026-0091 A 3 10.0 9.9 10.0 19 Jul 2026 3 Aug 2026
Shanghai ERP BiotechnologyCASE #VI-2026-0936 A 2 10.0 10.0 10.0 23 Dec 2025 7 May 2026
HomopeptideCASE #VI-2026-0760 A 5 9.9 9.9 10.0 24 May 2026 24 May 2026
Sangon BioCASE #VI-2026-0671 A 4 9.9 9.9 10.0 17 Mar 2026 2 Jul 2026
JEEP PeptidesCASE #VI-2026-0457 A 4 9.9 9.9 10.0 1 Jan 2026 3 Jul 2026
Shanghai Wibson BiotechnologyCASE #VI-2026-0379 A 4 9.9 9.9 10.0 8 May 2026 15 Jul 2026
WuXi TIDESCASE #VI-2026-0335 A 4 9.9 9.9 10.0 3 Nov 2025 25 Jul 2026
GenScript PeptidesCASE #VI-2026-0860 A 4 9.9 9.9 10.0 5 Mar 2026 9 Aug 2026
Mokemei BiotechnologyCASE #VI-2026-0540 A 3 9.9 9.9 10.0 26 Mar 2026 11 Jun 2026
QYAOBIOCASE #VI-2026-0861 A 2 9.9 9.9 10.0 5 Apr 2026 6 Jun 2026
BachemCASE #VI-2026-0314 A 2 9.9 9.9 10.0 15 May 2026 11 Jul 2026
Kerui PeptidesCASE #VI-2026-0626 A 2 9.9 9.9 10.0 13 Jun 2026 3 Jul 2026
Flourishglobal PeptideCASE #VI-2026-0630 A 2 9.9 9.9 10.0 13 Jun 2026 13 Jul 2026
Chinese Peptide CompanyCASE #VI-2026-0184 A 2 9.9 9.9 9.9 9 Apr 2026 7 Jun 2026
AmbioPharmCASE #VI-2026-0177 A 2 9.9 9.9 10.0 8 Apr 2026 8 Apr 2026
Qingdao Sigma Chemical QSCCASE #VI-2026-0538 A 4 9.4 8.7 10.0 23 May 2026 23 May 2026
Shanghai Sigma Audley SSACASE #VI-2026-0486 A 5 8.8 7.8 9.7 24 May 2026 24 May 2026
Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 A 8 8.3 6.5 9.5 24 May 2026 24 May 2026
Glbiochem (Shanghai)CASE #VI-2026-0704 A 4 8.3 7.6 9.1 23 May 2026 23 May 2026
Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 A 8 8.1 6.0 9.8 24 May 2026 24 May 2026
LN PeptidesCASE #VI-2026-0781 X 2 7.4 6.3 8.5 21 May 2025 25 May 2026
Skye PeptidesCASE #VI-2026-0451 X 2 7.2 6.6 7.8 8 Jul 2025 23 May 2026
Hangzhou Youngpeptide Biotechnology HYBCASE #VI-2026-0347 X 1 6.5 6.5 6.5 14 Jan 2025 14 Jan 2025
BeiBangAnCASE #VI-2026-0899 X 3 6.4 5.0 7.8 25 Apr 2025 24 May 2026
Peptide CraftersCASE #VI-2026-0994 X 2 5.8 4.7 6.8 16 Mar 2025 24 May 2026
LOOKBiotechCASE #VI-2026-0807 X 1 3.5 3.5 3.5 9 Jun 2025 9 Jun 2025
Marvel PeptideCASE #VI-2026-0507 X 1 0.0 0.0 0.0 7 May 2025 7 May 2025

Open any subject to view the batch-level evidence for Methylamine (base) CAS 74-89-5 alone.